Floatz logo

Ad5-yCD

Malignant Astrocytoma

Henry Ford Health SystemPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Malignant Astrocytoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2/3BB
Carboplatin
Oliver Jonas
Phase 2BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 1/2BB

View all 50 →

Same molecule, other indications

Ad5-yCD is also rated in:

prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
brain gliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →